What is Delcath Systems?
Delcath Systems, Inc. is a specialized interventional oncology company dedicated to the treatment of primary and metastatic liver cancers. The company's core technology revolves around the Delcath hepatic delivery system, designed to administer high-dose chemotherapy directly to the liver. This targeted approach aims to enhance treatment efficacy while potentially minimizing systemic side effects. Delcath's lead product candidate, melphalan hydrochloride for Injection, is being developed for use with this system. In Europe, the company offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan brand. Founded in 1988 and headquartered in New York, NY, Delcath Systems is focused on advancing therapeutic options for patients with challenging liver malignancies.
How much funding has Delcath Systems raised?
Delcath Systems has raised a total of $108.5M across 3 funding rounds:
Stock Offering
$7.2M
Other Financing Round
$85M
Series E
$16.3M
Stock Issuance/Offering (2000): $7.2M, investors not publicly disclosed
Other Financing Round (2023): $85M led by Logos Capital, BVF Partners, and Vivo Capital
Series E (2024): $16.3M, investors not publicly disclosed
Key Investors in Delcath Systems
Logos Capital
Logos Capital is a Miami-based impact investment firm dedicated to providing financial solutions that address global challenges. Established in 2011, the firm offers services in investment banking, private equity, trade finance, and project finance, targeting companies with positive social and environmental impacts.
BVF Partners
BVF Partners L.P. is a San Francisco-based private investment partnership specializing in fundamentally-driven public biotechnology investments. Since its inception in 1993, BVF has strived to build concentrated, long-term investments in small-cap biotechnology companies.
Vivo Capital
Vivo Capital, founded in 1996 and headquartered in Palo Alto, California, is a global healthcare investment firm focused on private and public equity as well as venture capital.
What's next for Delcath Systems?
With the recent major strategic investment and a substantial overall funding history, Delcath Systems is poised for significant advancement. The enterprise-level capital infusion suggests a focus on scaling operations, expanding clinical trials, and potentially preparing for broader market penetration. The company's strategic focus on targeted chemotherapy delivery for liver cancers aligns with a growing trend in precision medicine. Future developments will likely involve further clinical validation of their system, regulatory submissions, and the expansion of their commercial reach, particularly in key global markets. The company's trajectory indicates a strong commitment to innovation in oncology.
See full Delcath Systems company page
